COVID-19 Impact on Vaccines & Drugs Market

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 10)
    1.1 COVID-19 HEALTH ASSESSMENT
    1.2 COVID-19 ECONOMIC ASSESSMENT
    1.3 COVID-19 IMPACT ON THE ECONOMY—SCENARIO ASSESSMENT

2 COVID-19: DEVELOPMENT OF VACCINES (Page No. - 16)
    2.1 VACCINES
           2.1.1 CURRENT PIPELINE OF VACCINES
           2.1.2 COMPETITIVE LANDSCAPE (TOP PLAYERS DEVELOPING VACCINES)
                    2.1.2.1 Viewpoint on the COVID-19 pipeline
           2.1.3 MACROECONOMIC INDICATORS
                    2.1.3.1 Drivers
                               2.1.3.1.1 Increasing prevalence of infectious diseases
                               2.1.3.1.2 Growing funding for vaccine development
                    2.1.3.2 Restraints
                               2.1.3.2.1 High cost of vaccine development
                               2.1.3.2.2 Drugs and alternate therapies under development
                               2.1.3.2.3 Compassionate use
                               2.1.3.2.4 Immunization strategies
                    2.1.3.3 New opportunities
                               2.1.3.3.1 Collaborations among global organizations and vaccine manufacturers
                    2.1.3.4 Challenges
                               2.1.3.4.1 Herd immunity
           2.1.4 POST-COVID-19 VACCINE APPROVAL SCENARIO
                    2.1.4.1 Challenges in vaccine approval/production/supply
                               2.1.4.1.1 Are companies taking enough advantage of artificial intelligence (AI) to fast track vaccine/drug approval? (medium criticality)
                               2.1.4.1.2 Can production for pandemics be a challenge? (high criticality)
                               2.1.4.1.3 The world needs a vaccine but who needs it the most?(medium criticality)
                               2.1.4.1.4 Global organizations are expediting clinical research, but will site and logistical challenges cause delays?(high criticality)
                    2.1.4.2 Strategies to overcome challenges
                               2.1.4.2.1 Collaborations among global organizations
                               2.1.4.2.2 Establishing reliable supply chains
                               2.1.4.2.3 Historic examples (SARS, MERS, EBOLA, and H1N1)
                               2.1.4.2.4 Supply and Demand Issues during H1N1 Vaccination
                               2.1.4.2.5 Challenges in Supply Projections
                               2.1.4.2.6 Recommendations from the H1N1 Vaccination Program
                               2.1.4.2.7 Strategies adopted by several pharmaceutical companies to combat the H1N1 pandemic
                               2.1.4.2.8 Historic examples
                               2.1.4.2.9 New strategies
                    2.1.4.3 COVID-19 VACCINES MARKET (OPTIMISTIC, PESSIMISTIC, AND REALISTIC)
                               2.1.4.3.1 Market size estimation for optimistic scenario
                               2.1.4.3.2 Market size estimation for realistic scenario
                               2.1.4.3.3 Market size estimation for pessimistic scenario

3 COVID-19: DEVELOPMENT OF THERAPEUTIC DRUGS (Page No. - 42)
    3.1 COMPETITIVE LANDSCAPE (DRUGS MARKET)
           3.1.1 TOP PLAYERS INVOLVED IN THE DEVELOPMENT OF DRUGS FOR COVID-19
                    3.1.1.1 Sanofi and Regeneron Pharmaceuticals
                    3.1.1.2 Oncoimmune
                    3.1.1.3 Gilead Science
                    3.1.1.4 Sanofi and the National Institute of Respiratory Diseases (Mexico)
                    3.1.1.5 Roche
                    3.1.1.6 CytoDyn
                    3.1.1.7 Merck KGaA
                    3.1.1.8 Janssen Pharmaceuticals
                    3.1.1.9 Masterlek
                    3.1.1.10 Fujifilm
                    3.1.1.11 Ridgeback Biotherapeutics LP
                    3.1.1.12 AbbVie
                    3.1.1.13 Viewpoint on COVID-19 therapeutic drug pipeline
                    3.1.1.14 Impact of COVID-19 on other products in the portfolio/other under-development products
           3.1.2 MACROECONOMIC INDICATORS
                    3.1.2.1 Drivers
                               3.1.2.1.1 Alternate therapies targeting COVID-19
                               3.1.2.1.2 Adoption of organ-on-chip models in the development of drugs targeting COVID-19
                               3.1.2.1.3 Compassionate use
                               3.1.2.1.4 Collaborations and other developments promoting COVID-19 drugs
                    3.1.2.2 Restraints
                               3.1.2.2.1 Herd immunity and new vaccines under development
                               3.1.2.2.2 Uncertainty in the efficacy and side effects of repurposed malaria drugs targeting COVID-19
                    3.1.2.3 New opportunities
                               3.1.2.3.1 Adoption of new tools to expedite drug discovery
                               3.1.2.3.2 Investments in real-world evidence by pharmaceutical companies
                    3.1.2.4 Trends
                               3.1.2.4.1 Changes in ipr to promote the supply of essential drugs and medical supplies
           3.1.3 POST COVID-19 DRUG APPROVAL SCENARIO
                    3.1.3.1 Challenges in drug approval/production/supply
                               3.1.3.1.1 In the case of treatments being available for COVID-19, will they be available to the people in need? (high criticality)
                               3.1.3.1.2 Orphan drug status, market exclusivity – boon or bane?(medium criticality)
                               3.1.3.1.3 The world needs drugs targeting COVID-19. but who needs it the most (high criticality)
                    3.1.3.2 Strategies to overcome challenges
                               3.1.3.2.1 Production turbocharge of COVID-19 hopeful drugs
                               3.1.3.2.2 Accelerated approvals
                               3.1.3.2.3 Drug manufacturers initiating programs to increase the market access of COVID-19 drugs
                               3.1.3.2.4 Historic examples (SARS, MERS, EBOLA, and H1N1)
                               3.1.3.2.5 New strategies
                    3.1.3.3 Strategies to ramp up production at pandemic level
                               3.1.3.3.1 Establishing stable supply chains to ramp up production of drugs
                               3.1.3.3.2 Creating external manufacturing networks
           3.1.4 COVID-19 DRUGS MARKET ESTIMATION
                    3.1.4.1 Epidemiology model (assumption basis)
                    3.1.4.2 COVID-19 drugs market (optimistic, realistic, &  pessimistic scenarios)
                               3.1.4.2.1 Market size estimation for optimistic scenario
                               3.1.4.2.2 Market size estimation for realistic scenario
                               3.1.4.2.3 Market size estimation for pessimistic scenario

LIST OF TABLES (14 Tables)

TABLE 1 PIPELINE OF VACCINES FOR THE TREATMENT OF COVID-19
TABLE 2 INCIDENCE OF COVID-19 IN DIFFERENT COUNTRIES
TABLE 3 MAJOR INTERVENTIONAL VACCINE MANUFACTURING EFFORTS
TABLE 4 COVID-19 VACCINE MARKET, BY REGION, 2022-2025 (USD MILLION)
TABLE 5 COVID-19 VACCINE MARKET, BY REGION, 2022-2025 (USD MILLION)
TABLE 6 COVID-19 VACCINE MARKET, BY REGION, 2022-2025 (USD MILLION)
TABLE 7 COVID-19 THERAPEUTIC DRUG PIPELINE (CLINICAL)
TABLE 8 NOTABLE FIRST-TIME US APPROVAL DECISIONS PENDING IN MARCH 2020
TABLE 9 SUPPLEMENTARY AND OTHER NOTABLE APPROVAL DECISIONS PENDING  IN MARCH 2020
TABLE 10 NOTABLE FIRST-TIME US APPROVAL DECISIONS DUE IN APRIL 2020
TABLE 11 OTHER NOTABLE APPROVAL DECISIONS TO BE TAKEN IN APRIL 2020
TABLE 12 COVID-19 DRUGS MARKET, BY REGION, 2020–2025 (USD MILLION)
TABLE 13 COVID-19 DRUGS MARKET, BY REGION, 2020–2025 (USD MILLION)
TABLE 14 COVID-19 DRUGS MARKET, BY REGION, 2020–2025 (USD MILLION)

LIST OF FIGURES (15 Figures)

FIGURE 1 COVID-19 THE GLOBAL PROPAGATION
FIGURE 2 COVID-19 PROPAGATION: SELECT COUNTRIES
FIGURE 3 COUNTRIES BEGIN WITH SIMILAR TRAJECTORIES BUT CURVES DEVIATE BASED ON MEASURES TAKEN
FIGURE 4 REVISED GDP FORECASTS FOR SELECT G20 COUNTRIES IN 2020
FIGURE 5 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 6 SCENARIOS IN TERMS OF RECOVERY OF THE GLOBAL ECONOMY
FIGURE 7 PIPELINE OF COVID-19 VACCINE CANDIDATES, BY TECHNOLOGY PLATFORM
FIGURE 8 COVID-19 VACCINE DEVELOPERS, BY TYPE AND GEOGRAPHIC LOCATION
FIGURE 9 COVID-19 IMPACT ON VACCINE SUPPLY
FIGURE 10 EPIDEMIOLOGY MODEL (ASSUMPTION BASIS)
FIGURE 11 MOLECULES TARGETING COVID-19, BY CLINICAL PHASE
FIGURE 12 MAJOR LOCATIONS WHERE CLINICAL TRIALS ARE BEING CONDUCTED
FIGURE 13 SHARE OF MAJOR MOLECULAR ENTITIES UNDER DEVELOPMENT FOR COVID-19
FIGURE 14 SHARE OF MOLECULES UNDER PRECLINICAL DEVELOPMENT FOR COVID-19
FIGURE 15 SHARE OF REPURPOSED DRUGS VS. NEW ENTITIES

The global vaccines and drugs market study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the COVID Vaccines and Drugs market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the vaccines and infectious disease drugs market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents is provided below:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a bottom-up approach (epidemiology analysis) and assessment of utilization/adoption/penetration trends by region.

Data Triangulation

After arriving at the market size, the vaccines and drugs targeting COVID-19 market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments.

Objectives of the Study

• To define, describe, and forecast the global COVID Vaccines and Drugs market by region in optimistic, pessimistic and realistic scenarios
• To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of the COVID Vaccines and Drugs market in four major regions (North America, Europe, Asia-Pacific, and the Rest of the World)
• To profile the key players in the global COVID Vaccines and Drugs market and comprehensively analyze their key products in the pipeline
• To track and analyze competitive developments such as current product pipeline, clinical development stage, molecule type, geographic locations, etc.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

• Further breakdown of the Asia-Pacific COVID Vaccines and Drugs market into Japan, China, India, and other Asian countries
• Further breakdown of the European COVID Vaccines and Drugs market into the UK, France, Germany, Italy, and other European countries.